{"id":"anlotinib-hydrochloride-capsule-tqb2450-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (from PD-L1 inhibitor)"}]},"_chembl":{"chemblId":"CHEMBL5572229","moleculeType":null,"molecularWeight":"443.91"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anlotinib inhibits multiple receptor tyrosine kinases (VEGFR, FGFR, PDGFR, c-Kit) to suppress tumor neovascularization and growth. TQB2450 is a humanized monoclonal antibody targeting PD-L1 that blocks the PD-1/PD-L1 immune checkpoint, allowing T cells to recognize and attack cancer cells. The combination leverages both anti-angiogenic and immunotherapeutic mechanisms.","oneSentence":"Anlotinib is a multi-target tyrosine kinase inhibitor combined with TQB2450, a PD-L1 inhibitor, to block tumor angiogenesis and enhance anti-tumor immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:41.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced non-small cell lung cancer"},{"name":"Other solid tumors (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT05481645","phase":"PHASE2","title":"Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-08-26","conditions":"Advanced Endometrial Cancer, Sarcoma of Uterus","enrollment":71},{"nctId":"NCT04574284","phase":"PHASE2","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-09-29","conditions":"Advanced Endometrial Cancer","enrollment":170},{"nctId":"NCT04523272","phase":"PHASE3","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-08-25","conditions":"Advanced Renal Cancer","enrollment":528},{"nctId":"NCT06469879","phase":"PHASE3","title":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-09","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":358},{"nctId":"NCT06475599","phase":"PHASE3","title":"Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-07","conditions":"Endometrial Cancer","enrollment":420},{"nctId":"NCT06222944","phase":"PHASE2","title":"Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2024-02-25","conditions":"Gastric Cancer, Adenocarcinoma of Esophagogastric Junction","enrollment":90},{"nctId":"NCT05942508","phase":"PHASE1","title":"A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy","status":"UNKNOWN","sponsor":"Jinming Yu","startDate":"2023-05-30","conditions":"Limited Stage Small Cell Lung Cancer, Not Progressed After First-line Chemoradiotherapy","enrollment":20},{"nctId":"NCT05913089","phase":"PHASE2","title":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-06-14","conditions":"Non Small Cell Lung Cancer","enrollment":58},{"nctId":"NCT05718167","phase":"PHASE3","title":"TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-02","conditions":"Advanced Squamous Non-Small Cell Lung Carcinoma","enrollment":570},{"nctId":"NCT05252078","phase":"PHASE2","title":"Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients","status":"RECRUITING","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2022-06-02","conditions":"Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Esophageal Diseases","enrollment":30},{"nctId":"NCT05111366","phase":"PHASE2","title":"TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection","status":"UNKNOWN","sponsor":"Xianhai Mao","startDate":"2022-01-06","conditions":"Hepatocellular Carcinoma, Adjuvant Therapy","enrollment":37},{"nctId":"NCT05346952","phase":"PHASE3","title":"A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-01-25","conditions":"Advanced Non-squamous Non-small Cell Lung Cancer","enrollment":390},{"nctId":"NCT05145218","phase":"PHASE3","title":"A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-09-28","conditions":"Recurrent Platinum-resistant Ovarian Cancer","enrollment":405},{"nctId":"NCT04964479","phase":"PHASE3","title":"A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-08-06","conditions":"Non Small Cell Lung Cancer","enrollment":375},{"nctId":"NCT04888546","phase":"PHASE1, PHASE2","title":"TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-04-30","conditions":"Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi","enrollment":20},{"nctId":"NCT04809142","phase":"PHASE3","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-02-04","conditions":"Advanced Biliary Cancer","enrollment":392},{"nctId":"NCT04405505","phase":"PHASE3","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-06-01","conditions":"Triple Negative Breast Cancer","enrollment":332},{"nctId":"NCT03825705","phase":"PHASE1, PHASE2","title":"A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-04-23","conditions":"Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT03855358","phase":"PHASE1","title":"A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-05-09","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Anlotinib hydrochloride capsule + TQB2450 injection","genericName":"Anlotinib hydrochloride capsule + TQB2450 injection","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anlotinib is a multi-target tyrosine kinase inhibitor combined with TQB2450, a PD-L1 inhibitor, to block tumor angiogenesis and enhance anti-tumor immune response. Used for Advanced non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}